View on market: Stay Cautious, be with quality business:

U.S. futures fell while Asian stocks were mixed as crude oil prices rose, as the war in Ukraine neared the end of its first month and investors tracked geopolitical tensions in the Middle East. Australian equities advanced while South Korean shares were volatile. The moves signal a pause to the best weekly performance in global equities in over 15 months. Singapore-traded SGX Nifty, an early barometer of India’s benchmark Nifty 50 index, rose 1.21% to 17,490.50 points as of 6:30 am. Nymex crude rose to nearly $107 per barrel while bitcoin is hovering around $41,400. Focus will shift to U.S. Federal Reserve Chair Jerome Powell, who is to delivered a speech later today. This come a week after Fed effected a 25 basis-point rate hike to kickstart the monetary policy renormalisation.

Economic Calendar:

  • INR: Forex Reserve on 25th March 2022.
  • INR: Forex Reserve on 1st April 2022.
  • USD: FOMC Member William Speaks 22nd March, 2022.
  • USD:Jobless Claims on 24th March, 2022.

Brokerage Radar:

MORGAN STANLEY ON IT (Accenture earnings): A guidance increase for FY22 amid current macro volatility provides comfort around resilience in spends Slowdown in outsourcing booking & tighter margin guidance vs previously shows that supply-side challenges were offsets Read as +ve sentiment.

KOTAK INST EQUITIES ON THERMAX: Add, TP Rs 2270 Raise TP factoring vol benefits from TMX’s entry into SRU EPC biz through its $150m order win Tight capacity utilization yielded by a strong backlog boosts case for TMX upping its bid margin, which keep as a buffer for now.

MORGAN STANLEY ON SOBHA: Overweight, TP Rs 1095 Expect to benefit from ongoing residential upcycle given its large inventory of ongoing projects & new launch pipeline Price increases & new project acquisitions should help grow NAVs Its b/s has stabilized from net debt reduction over past few qtrs.

CLSA ON VEDANTA: O-P, TP Rs 400 Management meet takeaways Sounded confident in reducing debt at parent Vedanta Resources (VRL) by US$4bn over next 3 years largely through dividend inflows. It denied any further inter-company loans

International Markets:

U.S & Europe:

Particulars 17th Mar Chg Chg(%)
Nasdaq 13,893.84 279.06 2.05
Dow 34754.93 274.17 0.80
FTSE 7,404.73 19.39 0.26
CAC 6,620.24 7.72 0.12
DAX 14,413.09 25.03 0.17
Dow Fut.* 34627.00 -127.9 -0.36

Asian markets:

Particulars 21st Mar Chg. Chg(%)
SGX Nifty 17,379.00 97 0.56
Nikkei 26,827.43 174.54 0.65
Straits Times 3,338.61 7.98 0.24
Hang Seng 21,494.29 81.89 0.38
Shanghai 3,260.07 9 0.28

ADR Watch: 

Particulars 17th Mar Chg. Chg.(%)
Dr Reddy 53.55 0.09 0.17
HDFC Bank 62.88 1.01 1.63
ICICI Bank 18.98 0.13 0.69
Infosys 25.04 0.55 2.25
Tata Motor 28.59 0.51 1.82
Wipro 8.03 0.09 1.13

Commodities & Currency:

Particulars Current Price Chg(%)
USD/INR 75.80 -0.62
Brent 111.09 2.90
Gold 1925.90 -0.18
Silver 25.207 0.48


Particulars 17th Mar 16th Mar
FIIs 311.99 311.99
DIIs 772.55 772.55

News Update:

Adani Group stocks: The Gautam Adani-led conglomerate is exploring potential partnerships in Saudi Arabia, including the possibility of buying a stake in Saudi Aramco, Bloomberg reported citing people with knowledge of the matter.

Indian Oil, BPCL, HPCL: The price of diesel sold to bulk users has been hiked by about Rs 25 per litre in line with a near 40% rise in international oil prices, but retail rates at petrol pumps remain unchanged, PTI reported citing sources.

Cochin Shipyard: The company signed an agreement with Dredging Corporation of India to build India’s largest dredger in collaboration with IHC Holland. The project cost is Rs 950 crore.

Jubilant Pharmova: The company’s wholly owned subsidiary Jubilant Pharma through its subsidiary Jubilant Cadista Pharmaceuticals has received final approval for Doxepin.

Tata Consultancy Services: The company has reappointed Rajesh Gopinathan as managing director and chief executive officer and extended N Ganapathy Subramaniam’s appointment as chief operating officer for five years.

Tata Steel: The company acquired 10 crore 0.01% non-convertible redeemable preference shares of face value Rs 100 each of Tata Steel Long Products for Rs 1,000 crore.

Bharat Electronics: The company declared second interim dividend of Rs 1.5 per share.

SRF: The company has incorporated wholly owned subsidiary SRF Altech to engage in the business of manufacture of aluminium foil.

RBL Bank: The bank has extended interim Managing Director and CEO Rajeev Ahuja’s tenure by three months with effect from March 25.

Torrent Pharma: The company has signed a licence agreement to use the patents and know-how of Nirmatrelvir with UN-backed Medicines Patent Pool for manufacture and commercialisation of generic version of Paxlovid in 95 countries including India for treatment and/or prevention of Covid-19.

Aurobindo Pharma: The company has signed sub-licence agreement for a generic version of Pfizer’s Covid-19 oral treatment Nirmatrelvir with the UN-backed Medicines Patent Pool, for manufacturing and supplying the generic drug product to 95 countries including India.

Ashok Leyland: Sells Rs 200 crore 5Y Bonds at 7.30%.

Source: Moneycontrol, Livemint,, Bloomberg, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited,
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting, or emailing with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website:
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL